Source:http://linkedlifedata.com/resource/pubmed/id/19571508
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
6
|
pubmed:dateCreated |
2009-7-2
|
pubmed:abstractText |
Imatinib mesylate has significantly improved the outcome of patients with CML. In the IRIS trial, major molecular response (MMR), which is defined as the achievement of > or =3 log reduction in bcr-abl mRNA from the standardized baseline, was observed in 40% of CML patients by 12 months. Achievement of an MMR at 18 months is associated with 100% probability of transformation-free survival at 60 months, and MMR is an important goal of therapy. The nucleic acid quantitative "DNA probe FR Amp-CML" kit based on the transcription-mediated amplification method, can measure major bcr-abl mRNA in peripheral blood leukocytes. In this study, we studied the clinical usefulness of Amp-CML for monitoring minimum residual disease by comparison with the European standard nucleic acid quantitative method and real-time quantitative PCR (RQ-PCR) with GAPDH as an internal control, using peripheral leukocytes obtained from patients receiving imatinib treatment. The results indicated that Amp-CML had a significant correlation with Fusion Quant M-BCR (R>0.971, P<0.01), a standard nucleic acid quantitative method used in Europe and RQ-PCR (R>0.974, P<0.01), especially in samples with more than 100 copies/microg RNA of major bcr-abl mRNA. These data suggest that Amp-CML is reliable for monitoring major bcr-abl mRNA in patients having achieved an MMR.
|
pubmed:language |
jpn
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Fusion Proteins, bcr-abl,
http://linkedlifedata.com/resource/pubmed/chemical/Piperazines,
http://linkedlifedata.com/resource/pubmed/chemical/Pyrimidines,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Messenger,
http://linkedlifedata.com/resource/pubmed/chemical/Reagent Kits, Diagnostic,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Markers, Biological,
http://linkedlifedata.com/resource/pubmed/chemical/imatinib
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jun
|
pubmed:issn |
0485-1439
|
pubmed:author |
pubmed-author:?ZZ,
pubmed-author:BessyoMasamiM,
pubmed-author:IshikawaMahoM,
pubmed-author:JinnaiIturohI,
pubmed-author:KatoChiakiC,
pubmed-author:KyoTaiichiT,
pubmed-author:MiyamuraKouichiK,
pubmed-author:NiwaToshihiroT,
pubmed-author:OguraKenjiK,
pubmed-author:SasakiHiroshiH,
pubmed-author:YagasakiFumiharuF
|
pubmed:issnType |
Print
|
pubmed:volume |
50
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
481-7
|
pubmed:meshHeading |
pubmed-meshheading:19571508-Antineoplastic Agents,
pubmed-meshheading:19571508-Fusion Proteins, bcr-abl,
pubmed-meshheading:19571508-Humans,
pubmed-meshheading:19571508-Leukemia, Myelogenous, Chronic, BCR-ABL Positive,
pubmed-meshheading:19571508-Leukocytes,
pubmed-meshheading:19571508-Nucleic Acid Amplification Techniques,
pubmed-meshheading:19571508-Piperazines,
pubmed-meshheading:19571508-Polymerase Chain Reaction,
pubmed-meshheading:19571508-Pyrimidines,
pubmed-meshheading:19571508-RNA, Messenger,
pubmed-meshheading:19571508-Reagent Kits, Diagnostic,
pubmed-meshheading:19571508-Tumor Markers, Biological
|
pubmed:year |
2009
|
pubmed:articleTitle |
[Correlation of quantification of major bcr-abl mRNA between TMA (transcription mediated amplification) method and real-time quantitative PCR].
|
pubmed:affiliation |
Department of Hematology, Saitama Medical University International Medical Center.
|
pubmed:publicationType |
Journal Article,
English Abstract
|